1). Aletaha D., Neogi T., Silman AJ., Funovits J., Felson DT., Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010. 62:2569–81.

2). Rudwaleit M., LandeweA R., van der Heijde D., Listing J., Brandt J., Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009. 68:770–6.

3). Kim HO., Kang KY., Ju JH., Kim HY., Park SH. The incidence of serious infection among rheumatoid arthritis patients exposed to tumor necrosis factor antagonists. J Korean Rheum Assoc. 2010. 17:246–53.

4). Bongartz T., Sutton AJ., Sweeting MJ., Buchan I., Matteson EL., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006. 295:2275–85.

5). Strangfeld A., Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol. 2006. 20:1181–95.

6). Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005. 52:3403–12.

7). Dixon WG., Watson K., Lunt M., Hyrich KL., Silman AJ., Symmons DP, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006. 54:2368–76.

8). Leombruno JP., Einarson TR., Keystone EC. The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009. 68:1136–45.

9). Strangfeld A., Listing J., Herzer P., Liebhaber A., Rockwitz K., Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009. 301:737–44.

10). Doran MF., Crowson CS., Pond GR., O'Fallon WM., Gabriel SE. Frequency of Infection in patients with rheumatoid arthritis compared with controls: a population based Study. Arthritis Rheum. 2002. 46:2287–93.